This indicates that down-regulation of CD47 in gefitinib-treated NSCLC cells is per se sufficient to enhance antitumor immunity by improving cell recognition and engulfment by immune phagocytes. This evidence concerns the gene CD47 and non-small cell lung carcinoma.